Zipalertinib plus chemotherapy improves PFS and ORR in REZILIENT-3
Phase 3 REZILIENT 3 reported that zipalertinib plus chemotherapy significantly improved progression-free survival and response rates versus chemotherapy alone in metastatic EGFR exon 20 insertion NSCLC.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.